KEYTRUDA
AssessTechniques
Pembrolizumab, an immunotherapy drug used in combination cancer treatment.
Why it's here
Placed in Assess: 1 article(s) of evidence from 1 source(s), led by research breakthroughs, with 0 in the last 30 days. Confidence 24%. Low accumulated evidence, so it defaults conservatively pending more signal.
Evidence (1)
- 9Hacker News·8/19/2026breakthroughModerna reports positive Phase 3 melanoma trial for mRNA cancer therapy
Moderna and Merck announced positive topline Phase 3 results for intismeran autogene, an individualized mRNA neoantigen therapy used with KEYTRUDA in patients with completely resected stage IIB-IV melanoma. The trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, marking the first positive Phase 3 result for an individualized neoantigen therapy and an mRNA-based cancer therapy.